US Drug Recall Register

FDA Drug Recalls

14,801 recalls, newest first

Class II · Moderate risk Terminated

Progesterone Capsules

Reason Failed Dissolution Specifications: Out-of-specification results observed for dissolution during stability testing.

Dr. Reddy's Laboratories, Inc. NDC 43598-350-01 D-0292-2021
Class III · Low risk Terminated

Cequa

Reason Subpotent

Sun Pharmaceutical Industries INC NDC 47335-506-96 D-0289-2021
Class III · Low risk Terminated

Methylprednisolone Tablets USP

Reason Labeling: Illegible label: Customer complaint received of mis-alignment print of the printed dosing instructions on the blister card.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-001-03 D-0298-2021
Class II · Moderate risk Terminated

Daytrana

Reason Defective Delivery System: Out of specification for mechanical peel.

Noven Pharmaceuticals Inc NDC 68968-5555-3 D-0296-2021
Class II · Moderate risk Terminated

Daytrana

Reason Defective Delivery System: Out of specification for mechanical peel.

Noven Pharmaceuticals Inc NDC 68968-5554-3 D-0295-2021
Class II · Moderate risk Terminated

Daytrana

Reason Defective Delivery System: Out of specification for mechanical peel.

Noven Pharmaceuticals Inc NDC 68968-5553-3 D-0294-2021
Class II · Moderate risk Terminated

Daytrana

Reason Defective Delivery System: Out of specification for mechanical peel.

Noven Pharmaceuticals Inc NDC 68968-5552-3 D-0293-2021
Class III · Low risk Terminated

Atorvastatin Calcium Tablets

Reason Failed Impurities/Degradation Specifications:presence of ATV cyclo IP and FP, Dihydroxy epoxy and Dieto epoxy impurities

Dr. Reddy's Laboratories, Inc. NDC 55111-123-90 D-0291-2021
Class I · High risk Terminated

Acyclovir Sodium Injection 500mg/10mL

Reason Crystallization: customer complaints for crystallization in finished product.

Zydus Pharmaceuticals (USA) Inc NDC 68382-048-01 D-0316-2021
Class I · High risk Terminated

Acyclovir Sodium Injection 1000mg/20mL

Reason Crystallization: customer complaints for crystallization in finished product.

Zydus Pharmaceuticals (USA) Inc NDC 68382-049-01 D-0315-2021
Class III · Low risk Terminated

Methacholine Challenge 5-Syringe Test Kits

Reason Temperature Abuse; labeled with the incorrect room temperature (15-25 ¿C) storage conditions rather than the correct refrigerated (2 - 8 ¿C) storage conditions

Edge Pharma, LLC NDC 05446-1600-05 D-0306-2021
Class II · Moderate risk Terminated

Fludeoxyglucose F 18 Injection

Reason Lack of Assurance of Sterility

The General Hospital Corporation NDC 76318-334-50 D-0288-2021
Class II · Moderate risk Terminated

Imatinib Mesylate Tablets 100mg

Reason Failed Dissolution Specifications

Dr. Reddy's Laboratories, Inc. NDC 43598-344-90 D-0287-2021
Class I · High risk Terminated

Adam's Secret Extra Strength 3000

Reason Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and sildenafil.

Adams.Secret.co D-0311-2021
Class I · High risk Terminated

Adam's Secret Extra Strength 1500

Reason Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and sildenafil.

Adams.Secret.co D-0310-2021
Class II · Moderate risk Terminated

Metoclopramide Injection USP

Reason Chemical contamination; Unknown brown residue adhering to the inside of one vial.

Teva Pharmaceuticals USA NDC 0703-4502-01 D-0297-2021
Class II · Moderate risk Terminated

Leucovorin Calcium for Injection

Reason Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Teva Pharmaceuticals USA NDC 0703-5145-01 D-0285-2021
Class II · Moderate risk Terminated

MethyIPREDNISolone Acetate Injectable Suspension USP

Reason Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Teva Pharmaceuticals USA NDC 0703-0063-01 D-0284-2021
Class II · Moderate risk Terminated

MethyIPREDNISolone Acetate Injectable Suspension USP

Reason Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Teva Pharmaceuticals USA NDC 0703-0043-01 D-0283-2021
Class II · Moderate risk Terminated

MethyIPREDNISolone Acetate Injectable Suspension USP

Reason Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Teva Pharmaceuticals USA NDC 0703-0045-01 D-0282-2021
Class II · Moderate risk Terminated

MethyIPREDNISolone Acetate Injectable Suspension USP

Reason Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Teva Pharmaceuticals USA NDC 0703-0051-01 D-0281-2021
Class II · Moderate risk Terminated

Epoprostenol Sodium for Injection

Reason Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Teva Pharmaceuticals USA NDC 0703-1995-01 D-0280-2021
Class II · Moderate risk Terminated

Vecuronium Bromide for Injection

Reason Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Teva Pharmaceuticals USA NDC 0703-2914-01 D-0279-2021
Class II · Moderate risk Terminated

Toposar

Reason Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Teva Pharmaceuticals USA NDC 0703-5657-01 D-0278-2021
Class II · Moderate risk Terminated

Metoclopramide Injection USP

Reason Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Teva Pharmaceuticals USA NDC 0703-4502-01 D-0277-2021